



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Grillo-Lopez, et al.

Group Art Unit: 1642

Application Serial No. 09/762,587

Examiner: M. Davis

Filed: September 6, 2001

Title: COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING
ADMINISTRATION OF ANTI-CD20 ANTIBODY

RESPONSE TO RESTRICTION/ELECTION REQUIREMENT

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Office Action [Election of Species Requirement] Applicants elect, with traverse, Group II claims 7-9, drawn to a method for treating a subject having B-cell lymphoma, which subject has not exhibited appreciable tumor remission or regression after administering a chimeric anti-CD20 antibody, comprising administering a radiolabeled anti-CD20 antibody. The traversal is on the basis that all of the groups are directed to related methods for treating B cell lymphoma that involve the administration of anti-CD20 antibody. Applicants further elect the species of intermediate grade NHL.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: Robin L. Teskin
Robin L. Teskin
Registration No. 35,030

1600 Tysons Boulevard
McLean, Virginia 22102
(703) 905-2000
(703) 905-2500 Facsimile

Date: January 6, 2003

RECEIVED
JAN 09 2003
TECH CENTER 1600/2500

inventor(s): Grillo-Lopez, et al.

Appl. No.: 09

762,587

Series Code: ↑

Serial No.: ↑

Filed: September 6, 2001

Hon. Commissioner of Patents
Washington, D.C. 20231

Group Art Unit: 1642

Examiner: M. Davis

Atty. Dkt. P 277847 1998-30-0523

M#

Client Ref

Appl. Title: Combination Therapies for B-cell
Lymphomas Comprising Administration
of Anti-CD20 Antibody

Sir:

REPLY/AMENDMENT/LETTER

Date: January 6, 2003

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim
- A. ☒ NOT made
- B. ☐ Withdrawn
- C. ☐ made herewith
- D. ☐ made previously
- For B & C
See **Required
Separate Paper**
(Pat-256)

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	**minus 0	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	***minus 0	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)..... add			+ \$280/\$140 =	+ \$0	104/204
5. Original due Date: December 5, 2002 <input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached			(1 mo) \$110/\$55 = (2 mos) \$400/\$200 = (3 mos) \$920/\$460 = (4 mos) \$1,440/\$720 = (5 mos) \$1,960/\$980 =	+ \$110	115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract			- \$0		
8.			Extension Fee	+ \$110	
9. If Terminal Disclaimer attached, add Rule 20(d) official fee			+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c). add			+ \$180	+ \$0	126
or if Rule 97(d) Request			+ \$180		126
11. After-Final Request Fee per rules 129(a) and 17(r)			+ \$740/370	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b)			x \$740/370 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)			+ \$740/370	+ \$0	1179/1279
14. Petition fee for				+ \$0	
15			TOTAL FEE = \$110		
16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0"					
17. *If the "Highest number previously paid for" in this space is less than 20, write "20" in this space					
18. *If the "Highest number previously paid for" in this space is less than 3, write "3" in this space					

Our Deposit Account No. 03-3975)
(Our Order No. 037003 277847
C# M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

P.O. Box 10500

McLean, VA 22102

Tel: (703) 905-2000

By Atty: Robin L. Teskin

Sig:

Reg. No. 35,030

Fax: (703) 905-2500

Tel: (703) 905-2200

Atty/Sec: RLT/DJM

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments